# RNK05047

Source: https://onco.cc/drugs/rnk05047/  
OnCo record `rnk05047` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.

## Summary

RNK05047 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd., in metastatic cancer. A targeted protein degrader, as described in the registry record: it tags a cancer-driving protein for destruction by the cell's own disposal system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: RNK05047
- Modality: Targeted protein degrader
- Mechanism: A targeted protein degrader, as described in the registry record: it tags a cancer-driving protein for destruction by the cell's own disposal system.

## Sources

- ClinicalTrials.gov: trials of RNK05047: https://clinicaltrials.gov/search?intr=RNK05047

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)](https://onco.cc/trials/nct05487170/)

---
JSON: https://onco.cc/api/v1/entities/rnk05047.json